Skip to main content
Fig. 2 | BMC Neurology

Fig. 2

From: Opicapone versus placebo in the treatment of Parkinson’s disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial

Fig. 2

Timelines of study assessments. aV2 is divided in V2a and V2b. If ON/OFF diary entries are non-compliant at V2a, the patient will be re-trained on correct use of the diary and visit V2b will be postponed for 3–4 days. If diary completion is satisfactory at V2a, V2b is performed immediately on the same day. CGI-C, Clinical Global Impression of Change; DDCI, dopa decarboxylase inhibitor; EMD, early morning dystonia; KPPS, King’s Parkinson’s Disease Pain Scale; L-dopa, levodopa; MDS-NMS, Movement Disorder Society-sponsored Non-Motor rating Scale; MDS-UPDRS, Movement Disorder Society-sponsored Unified Parkinson’s Disease Rating Scale; PDQ-8, 8-item Parkinson’s Disease Questionnaire; PGI-C, Patient’s Global Impression of Change; PSV, post-study visit; V, visit

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us